NICHOLAS BEYDA to Antifungal Agents
This is a "connection" page, showing publications NICHOLAS BEYDA has written about Antifungal Agents.
Connection Strength
3.049
-
Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata. Microbiol Spectr. 2022 02 23; 10(1):e0183721.
Score: 0.645
-
In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. J Clin Microbiol. 2018 08; 56(8).
Score: 0.506
-
Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
Score: 0.408
-
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb; 68(2):438-43.
Score: 0.339
-
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1086-96.
Score: 0.333
-
Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. Diagn Microbiol Infect Dis. 2019 Nov; 95(3):114861.
Score: 0.135
-
Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother. 2019 07 01; 74(7):1904-1910.
Score: 0.135
-
Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 09; 14:58-64.
Score: 0.123
-
Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study. Antimicrob Agents Chemother. 2018 01; 62(1).
Score: 0.121
-
Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr; 349(4):316-20.
Score: 0.100
-
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
Score: 0.095
-
Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species. Pharmacotherapy. 2023 06; 43(6):466-472.
Score: 0.044
-
Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis. Eur J Clin Microbiol Infect Dis. 2022 Oct; 41(10):1207-1213.
Score: 0.042
-
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
Score: 0.023